Mind Medicine (mindmed) INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Definium Therapeutics reports increased net losses for 2025 while progressing its lead psychedelic-based drug candidates, DT120 and DT402, into pivotal clinical trials for anxiety, depression, and autism spectrum disorder.
MindMed's 2024 10-K filing highlights advancements in clinical trials for brain health disorders, including positive results for MM120 in GAD and initiation of Phase 3 trials.
Mind Medicine (MindMed) Inc. details its share capital, voting rights, dividend policy, and regulatory compliance in its latest 10-K filing.